Burkholderia Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Burkholderia Infections - Pipeline Review, H1 2016', provides an overview of the Burkholderia Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Burkholderia Infections - The report reviews pipeline therapeutics for Burkholderia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Burkholderia Infections therapeutics and enlists all their major and minor projects - The report assesses Burkholderia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Burkholderia Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Burkholderia Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Burkholderia Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Burkholderia Infections Overview 8 Therapeutics Development 9 Pipeline Products for Burkholderia Infections - Overview 9 Pipeline Products for Burkholderia Infections - Comparative Analysis 10 Burkholderia Infections - Therapeutics under Development by Companies 11 Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes 12 Burkholderia Infections - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Burkholderia Infections - Products under Development by Companies 16 Burkholderia Infections - Products under Investigation by Universities/Institutes 17 Burkholderia Infections - Companies Involved in Therapeutics Development 18 Arno Therapeutics, Inc. 18 Bavarian Nordic A/S 19 Emergent BioSolutions Inc. 20 Eumedica SA 21 Grifols, S.A. 22 NanoBio Corporation 23 Sarepta Therapeutics, Inc. 24 Soligenix, Inc. 25 Syntiron LLC 26 TGV-Laboratories 27 Vault Pharma Inc. 28 Burkholderia Infections - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 AR-13 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 ARD-3100 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 ARD-3150 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Burkholderia pseudomallei vaccine - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Burkholderia vaccine - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Burkholderia vaccine - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 dusquetide - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 EV-035 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 GC-072 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 melioidosis vaccine - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Mul-1867 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 NB-401 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 SGX-101 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 SGX-943 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 temocillin - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 VPI-231 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Burkholderia Infections - Dormant Projects 68 Burkholderia Infections - Discontinued Products 69 Burkholderia Infections - Product Development Milestones 70 Featured News & Press Releases 70 May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis 70 Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 70 Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072 71 Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 71 Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 71 Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 72 Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 72 Oct 15, 2009: NanoBio's Nanoemulsion Kills Drug-Resistant Bacteria Found In Cystic Fibrosis Patients 73 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 75 Disclaimer 76
List of Tables
Number of Products under Development for Burkholderia Infections, H1 2016 9 Number of Products under Development for Burkholderia Infections - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Comparative Analysis by Unknown Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Burkholderia Infections - Pipeline by Arno Therapeutics, Inc., H1 2016 18 Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H1 2016 19 Burkholderia Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 20 Burkholderia Infections - Pipeline by Eumedica SA, H1 2016 21 Burkholderia Infections - Pipeline by Grifols, S.A., H1 2016 22 Burkholderia Infections - Pipeline by NanoBio Corporation, H1 2016 23 Burkholderia Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016 24 Burkholderia Infections - Pipeline by Soligenix, Inc., H1 2016 25 Burkholderia Infections - Pipeline by Syntiron LLC, H1 2016 26 Burkholderia Infections - Pipeline by TGV-Laboratories, H1 2016 27 Burkholderia Infections - Pipeline by Vault Pharma Inc., H1 2016 28 Assessment by Monotherapy Products, H1 2016 29 Number of Products by Stage and Target, H1 2016 31 Number of Products by Stage and Mechanism of Action, H1 2016 33 Number of Products by Stage and Route of Administration, H1 2016 35 Number of Products by Stage and Molecule Type, H1 2016 37 Burkholderia Infections - Dormant Projects, H1 2016 68 Burkholderia Infections - Discontinued Products, H1 2016 69
List of Figures
Number of Products under Development for Burkholderia Infections, H1 2016 9 Number of Products under Development for Burkholderia Infections - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 29 Number of Products by Targets, H1 2016 30 Number of Products by Stage and Targets, H1 2016 30 Number of Products by Mechanism of Actions, H1 2016 32 Number of Products by Stage and Mechanism of Actions, H1 2016 32 Number of Products by Routes of Administration, H1 2016 34 Number of Products by Stage and Routes of Administration, H1 2016 34 Number of Products by Molecule Types, H1 2016 36 Number of Products by Stage and Molecule Types, H1 2016 36
North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption ratRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.